Endothelial Dysfunction Market Size is valued at USD 1.84 Bn in 2022 and is predicted to reach USD 2.63 Bn by the year 2031 at a 4.1% CAGR during the forecast period for 2023-2031.
Endothelial dysfunction is a condition characterised by impaired or compromised functioning of the inner lining of blood vessels, the endothelium. The endothelium is essential for sustaining vascular health and regulating multiple physiological processes.
The growth of the endothelial dysfunction market is being driven by several reasons that highlight the vital importance of vascular health in the prevention of cardiovascular diseases. These forces reflect an increasing understanding of the impact of endothelium dysfunction on general well-being and the need to mitigate associated hazards.
The market's expansion is being driven by rising rates of cardiovascular disease, particularly as the population ages and becomes more vulnerable. Unhealthy lifestyle choices, obesity, and diabetes epidemics contribute to the demand for endothelial dysfunction therapies. Targeted medicines have been developed as a result of advances in medical research and clinical understanding. Early intervention, personalized therapy, and new treatment options drive the industry forward. Awareness campaigns, increased access to healthcare, and government measures all play important roles in altering the market landscape. The pharmaceutical and biotechnology industries are investing in research & and development, which will result in innovation.
Competitive Landscape
Some Major Key Players In The Endothelial Dysfunction Market:
- ZOLL Medical Corp
- Sphingo Tec GmbH
- Lawrence Berkeley National Laboratory
- The Polymath Co
- Endothelix Inc
- Perimed AB
- SMART Medical Ltd
- Everist Health Inc
- Alam Medical SaRi,
- Medizinische Messtechnik GmbH
Recent Developments:
- In April 2021, Berkeley Lab created a cuff-based monitoring system for endothelial function and endothelium-independent vasodilation. According to human studies, the cuff-based procedure is 37% more sensitive to arterial relaxation than brachial artery imaging.
Market Segmentation:
The Endothelial Dysfunction market has been segmented based on cause, test type, and end-user. The market is segmented as hypertension, diabetes, hypercholesterolemia, Baches's disease, obesity, and others based on the cause. The test type segment includes invasive tests and non-invasive tests. The end-user segment includes hospitals, ambulatory surgical centers, speciality clinics, and others.
Based On Test Type, The Standard Pen Needle Segment Is Accounted As A Major Contributor In The Endothelial Dysfunction Market
Endothelial dysfunction market share was higher in the invasive testing segment. Endothelial dysfunction is typically diagnosed via invasive diagnostics during coronary angiography. Vasoreactivity testing is the main focus of endothelial dysfunction testing. Vasoreactivity testing is the most clinically evident vascular endothelium function. Hence invasive studies are performed. Invasive tests are often performed using two techniques: intracoronary and intrabrachial vasoactive agent infusions. These methods are still regarded as the gold standard for detecting endothelium dysfunction early. These invasive procedures have been described in several cardiometabolic disease states linked to future atherosclerosis and other negative effects.
The Hypertension Segment Witnessed Growth At A Rapid Rate
As a silent killer, hypertension causes deadly cardiovascular illnesses. Hypertension is well acknowledged as one of the most common disorders among the elderly. The prevalence of hypertension rises dramatically with age. Ageing and high blood pressure are independent predictors of cardiovascular and cerebrovascular outcomes. Aging is linked to changes in vascular structure and function by various mechanisms, including oxidative stress, cell senescence, and inflammation. Furthermore, hypertension hastens ageing-related changes in vascular structure and function, particularly endothelial function.
In The Region, The North American Endothelial Dysfunction Market Holds A Significant Revenue Share
Geographically, the market for endothelial dysfunction products in North America and Europe is currently the leading market due to strong engagement in research and development, modern medical facilities, and widespread awareness of cardiovascular illnesses and other related conditions. The absence of government participation and funding for research and development has hampered emerging and developing economies' growth and revenue share. With a significant increase in cardiovascular and diabetes cases in Asia-Pacific and Middle Eastern countries in the coming years, the endothelial dysfunction market is expected to grow in these regions over the next 5-7 years.
Endothelial Dysfunction Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1.84 Bn |
|
Revenue Forecast In 2031 |
USD 2.63 Bn |
|
Growth Rate CAGR |
CAGR of 4.1% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Cause, Test Type, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
ZOLL Medical Corp, Sphingo Tec GmbH, Lawrence Berkeley National Laboratory, The Polymath Co, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, Alam Medical SaRi, and Medizinische Messtechnik GmbH. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
